Copyright
©The Author(s) 2021.
World J Clin Cases. Feb 6, 2021; 9(4): 919-926
Published online Feb 6, 2021. doi: 10.12998/wjcc.v9.i4.919
Published online Feb 6, 2021. doi: 10.12998/wjcc.v9.i4.919
Figure 1 Mammography findings.
A: Before treatment, no abnormal lesions were found in either breast and enlarged lymph node could be observed in the right axilla; B: After neoadjuvant chemotherapy + anlotinib, the targeted axillary lymph node was significantly smaller.
Figure 2 Magnetic resonance imaging finding.
No abnormal lesions were found in either breast.
Figure 3 Ultrasound of the targeted lymph node.
A: Before the second cycle of treatment; B: Before the fourth cycle of treatment; C: Before the sixth cycle of treatment; D: Before the eighth cycle of treatment; E: Before surgery. The targeted lymph node was significantly smaller following treatment with neoadjuvant chemotherapy + anlotinib.
Figure 4 Computed tomography scan.
A: Before treatment, the enlarged lymph node could be observed in the right axilla; B: After neoadjuvant chemotherapy + anlotinib, the targeted axillary lymph node was significantly smaller.
- Citation: Zhang Y, Wu D, Zhao B, Tian XL, Yao TC, Li F, Liu WF, Shi AP. Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature. World J Clin Cases 2021; 9(4): 919-926
- URL: https://www.wjgnet.com/2307-8960/full/v9/i4/919.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i4.919